Arzneiwerk AG VIDA (XETRA: TLIK.DE) AI-Powered Stock Analysis
See how Arzneiwerk AG VIDA scores across key metrics like financial growth, valuation, and market position on the XETRA, using AI-driven evaluation.
TLIK.DE●XETRA
TechnologyCommunication Equipment
€0.61
€0.03(4.27%)
German Market opens in 6h 11m
Arzneiwerk AG VIDA (XETRA: TLIK.DE) AI-Powered Stock Analysis
See how Arzneiwerk AG VIDA scores across key metrics like financial growth, valuation, and market position on the XETRA, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerArzneiwerk AG VIDA (XETRA: TLIK.DE) Stock Overall Grade
Arzneiwerk AG VIDA's grade for its XETRA listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Arzneiwerk AG VIDA's overall XETRA stock rating.
Forecast
C+Score
50/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
BScore
67/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Arzneiwerk AG VIDA (XETRA: TLIK.DE) AI-Powered Stock Analysis
On the XETRA, TLIK.DE demonstrates Good performance with an overall Forecast Score of 50/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (67/100, B) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), the XETRA-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(XETRA: TLIK.DE) Component Analysis Explained
Understand the key factors behind each Arzneiwerk AG VIDA (XETRA: TLIK.DE) stock grade, including financials, comparisons, and forecasts.